Recent studies have found an association between CYP2D6 genetic polymorphisms and hyperprolactinemia, especially in female pediatric populations who are poor CYP2D6 metabolizers (Grădinaru et al., 2019; Koller et al., 2020). This evidence concerns the gene CYP2D6 and hyperprolactinemia.